Navigation Links
Dissolvable Heart Artery Stents Appear Safe in Study
Date:4/16/2012

By Denise Mann
HealthDay Reporter

MONDAY, April 16 (HealthDay News) -- New long-term research now suggests that fully biodegradable stents are safe to use in heart arteries.

Reporting in the April 16 issue of Circulation, Japanese researchers said a 10-year study has shown the biodegradable Igaki-Tamai stent, made of a cornstarch-based material, dissolves into the artery wall, leaving no permanent foreign material in an artery and reducing the occurrence of an in-stent blood clot.

According to the study, survival rates from all causes was 87 percent and rates of major heart-related complications were similar to those seen with metal stents.

Stents, the tiny mesh tubes inserted into heart arteries to keep open and allow blood to flow to the heart, are far from fail-safe. New blockages can -- and do -- occur. So scientists have been trying to develop new stents, including ones coated with blood-thinning medications. Metal stents, sometimes coated with drugs, remain in the body where they can reclog.

The Igaki-Tamai stent, developed by Kyoto Medical Planning Co., is used in nine European Union countries and Turkey to treat peripheral artery disease, or blocked arteries in the legs. It is not used to treat blocked heart arteries in any country.

Study author Dr. Kunihiko Kosuga, director of cardiology at Shiga Medical Center for Adults in Moriyama City, predicted in a journal news release that "fully biodegradable stents may hold an important position as the next generation of coronary devices."

In the study, 50 people received 84 Igaki-Tamai stents between September 1998 and April 2000. Researchers report that the survival rate from heart-related death was 98 percent. Half of the individuals experienced major heart-related complications, which is in line with studies of metal stents. The stent was totally absorbed in three years.

"There is a risk of heart attack if a stent does not get incorporated into the blood vessel wall," explained Dr. Barry Kaplan, vice chairman of cardiology at North Shore University Hospital in Manhasset, N.Y., and Long Island Jewish Medical Center in New Hyde Park, N.Y. Once the metal stent is absorbed, the risk theoretically should decrease or go away. The problem is that metal stents are not always absorbed. In theory, biodegradable stents should be.

"The panacea would be a drug-eluding biodegradable stent where the drug is released into the vessel wall before the stent gets absorbed," he said. "This would lower the re-stenosis or re-blockage rate, yet eliminate risk of heart attacks or blood clot," Kaplan said. "From a technical standpoint, this particular stent is providing a similar risk to a bare-metal stent."

The new study is "helping us feeling more comfortable that this is a good line of research to pursue and that there is no special concern about hidden dark sides with this biodegradable stent," added Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City.

More information

What is a stent? Learn more from the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Kirk Garratt, M.D., clinical director of interventional cardiovascular research, Lenox Hill Hospital, New York City; Barry Kaplan, M.D., vice chairman of cardiology, North Shore University Hospital and Long Island Jewish Medical Center, New Hyde Park, N.Y.; April 16, 2012, Circulation


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. SMART heart eases heart ache, targets cardiac patients emotional well-being
2. Spouses of Cancer Patients May Have Raised Risk of Heart Disease, Stroke
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. EKG Heart Test May Predict Risk in Older Adults
5. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
6. Heart failure patients with diabetes may benefit from higher glucose levels
7. Invasive heart test being dramatically overused, Stanford study shows
8. In children born with severe heart defect, surgical management has little effect on neuro outcomes
9. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
10. Risk of suicide and fatal heart attack immediately following a cancer diagnosis
11. Witnessing, Experiencing Traumatic Events May Worsen Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dissolvable Heart Artery Stents Appear Safe in Study 
(Date:2/23/2017)... ... 2017 , ... Healthcare Research & Analytics® (HRA®) in cooperation ... cancer, has produced a seminal study that asked cancer survivors and their caregivers ... a webinar, Defining Compassionate Care Through the Voices of Patients and Advocates that ...
(Date:2/23/2017)... ... (PRWEB) ... opportunity for the nation to come together to combine its ... – with its favorite fruit – apples! To celebrate National ... to join the “Apple Madness” bracket tournament – a five-week, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... program today with a new Indiegogo campaign . Individuals are now able to ... the Los Angeles area, either as a participating patient or through an Indiegogo donation. ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez ... has also continued to spiritually evolve, which is the purpose of everyone in this ... Spiritual Truths ” (published by Balboa Press) attempts to guide readers to expand one’s ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Research and Markets has announced the ... Strategies - 2016" report to their offering. ... The latest research Autism Spectrum ... data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder and ...
(Date:2/23/2017)... MELBOURNE, Australia , Feb. 23, 2017 ITL Limited, ... to announce excellent results for the half year ended 31 December ... ITL BioMedical Growth Update" presentation can be viewed here . ... of $2.12m (Dec 2015: $1.04m; up 104%) Earnings ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology: